$14.490
+0.030 (+0.21%)At close
FOLD News
FOLD Events
BioMarin Acquires Amicus for $14.50 per Share
BioMarin Pharmaceutical(BMRN) said that it completed the previously announced agreement to acquire Amicus Therapeutics (FOLD) for $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8B. BioMarin expects to provide updated FY guidance during its Q1 earnings conference call on May 4.
Company Reports Q4 Revenue of $185.2M
Reports Q4 revenue $185.2M, consensus $185M. The company said, "Total revenues for the full year 2025 were $634.2 million, reflecting strong operational growth measured at constant exchange rates of 17% and a currency tailwind of ~$14 million. Fourth quarter total revenues were $185.2 million up 24%, or 20% at CER."
Amicus Therapeutics Presents New Data on Galafold and Pombiliti+ Opfolda at WORLDSymposium 2026
Amicus Therapeutics announced the presentation of new data from clinical and real-world studies of Galafold in Fabry disease and Pombiliti+ Opfolda in late-onset Pompe disease. Data are being presented at the 22nd Annual WORLDSymposium 2026. "Amicus continues to advance the science and understanding of both Fabry and Pompe diseases, and we are proud to showcase new data for our medicines at this year's WORLDSymposium. These new data add to the growing body of evidence supporting the important role of Galafold and Pombiliti + Opfolda," said Jeff Castelli, PhD, Chief Development Officer, Amicus Therapeutics. "We are immensely grateful to the patients, their families, and investigators whose partnership makes scientific research and advances possible."
Guggenheim Downgrades Amicus to Neutral on BioMarin's $14.50 Acquisition
Guggenheim downgraded Amicus (FOLD) to Neutral from Buy on the pending acquisition by BioMarin (BMRN) for $14.50 per share.
Major Averages Finish Broadly Lower as S&P 500 and Dow Hit Record Highs
The major averages finished broadly lower to begin the final trading week of the year after a strong rally that pushed the S&P 500 and Dow to record highs last week. Traders are wrestling with profit-taking in major tech and AI-linked names even as the broader benchmark indexes remain close to all-time peaks. Precious metals have pulled back, contributing to cautious positioning among risk assets, while energy and select cyclical names show pockets of relative strength.Looking to commodities, gold was sharply lower, retreating from record highs, while oil prices rallied toward $60 a barrel.Get caught up quickly on the top news and calls moving stocks with this Midday Fly By.STOCK NEWS:SoftBankDigitalBridgefor $16 per share in cashLululemonfounder Chip Wilsonof three independent director candidatesCoupangannounced a 1.69T KRWover data breachVeriskhasto acquire AccuLynxWALL STREET CALLS:Amicusto Market Perform at Leerink after takeover dealPalisade Biowith an Overweight at Piper SandlerTurn Therapeuticswith a Buy at D. Boral CapitalNorthland1stDibsat Market Perform, awaits "more robust growth"AROUND THE WEB:New Era Energy & Digitalas New Mexico AG Raul Torrez filed a lawsuit against the companyWhile consistently the number 2 warehouse-club company in the U.S., Walmart-ownedSam's Club has been able to beat out Costcoin China,Novo Nordiskhas cut the listing prices by half for its obesity drug Wegovy in some Chinese provinces as the company prepares for copycats to flood the market,Hyundaiis not in a position to repurchase its manufacturing plant in Russia due to the war in Ukraine,Airbusis producing aircraft at a rapid pace in the final days of the year as the company works to achieve its recently cut annual aircraft delivery goal,MOVERS:Eightcoincreases after its board of directors approved afor up to $125MAutolusgains in New York after Needham named the stock as itsEnergy Fuelshigher after providing anUltragenyxlower after announcing its Phase 3 Orbit and Cosmic studies for setrusumabINDEXES:The Dow fell 249.04, or 0.51%, to 48,461.93, the Nasdaq lost 118.75, or 0.50%, to 23,474.35, and the S&P 500 declined 24.20, or 0.35%, to 6,905.74.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.